RxDoctor Payments Data

Alexis McChurch, NP

Family · Nashville, TNNPI 1992149819

Payments from drug & device makers

$11,913in general payments, 2019–2025

Across 544 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • AstraZeneca$2K
  • GSK$2K
  • Actelion Pharmaceuticals US, Inc.$634
  • Sanofi$610
  • Grifols USA, LLC$592
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$11,913100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,913 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,902
Medicare patients
300
Services billed
956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter689$534,764
OfevNintedanib Esylate15$203,124
Breztri AerosphereBudesonide/Glycopyr/Formoterol118$83,580
Spiriva RespimatTiotropium Bromide81$53,037
Breo ElliptaFluticasone/Vilanterol81$35,197
Fluticasone-SalmeterolFluticasone Propion/Salmeterol196$34,500
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr61$32,675
Advair HfaFluticasone Propion/Salmeterol67$30,943
XareltoRivaroxaban22$20,409
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$20,318
Albuterol Sulfate HfaAlbuterol Sulfate598$15,886
Spiriva HandihalerTiotropium Bromide20$15,600
EliquisApixaban15$12,529
Wixela InhubFluticasone Propion/Salmeterol84$11,854
SymbicortBudesonide/Formoterol Fumarate33$10,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,529$602,636831 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$2,257$286,576159 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,606$94,158151 claims
Johnson & JohnsonXarelto$197$20,40922 claims
PfizerEliquis$123$12,52915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →